Protalix BioTherapeutics Treats First Patient in Trial of prGCD

Israeli biopharmaceutical company Protalix BioTherapeutics reported that it has treated the first patient in its Phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase for the treatment of Gaucher disease, a lysosomal storage disorder in humans.

According to Protalix, the Phase III clinical trial will take place in centers in the U.S., Israel and other locations.

The trial design consists of 30 patients in a randomized, double-blind, dose-ranging study, with two parallel groups, the company added.